polymerase chain reaction

Rearrangement of Immunoglobulin Genes in Tumor Cells of Patients with Primary Mediastinal (Thymic) Large B-Cell Lymphoma

LYMPHOID TUMORS , , ,

YaK Mangasarova, YuV Sidorova, AU Magomedova, BV Biderman, EE Nikulina, AB Sudarikov, AM Kovrigina, SK Kravchenko

National Medical Hematology Research Center, 4a Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167

For correspondence: Yana Konstantinovna Mangasarova, MD, PhD, 4a Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167; Tel.: +7(926)395-82-52; e-mail: v.k.jana@mail.ru

For citation: Mangasarova YaK, Sidorova YuV, Magomedova AU. Rearrangement of Immunoglobulin Genes in Tumor Cells of Patients with Primary Mediastinal (Thymic) Large B-Cell Lymphoma. Clinical oncohematology. 2019;12(3):271–7 (In Russ).

doi: 10.21320/2500-2139-2019-12-3-271-277

ABSTRACT

Background. Primary mediastinal (thymic) large B-cell lymphoma (PMBCL) is a malignant tumor with large atypical lymphoid cells expressing post-germinal differentiation markers. Rearrangements of immunoglobulin genes in PMBCL are revealed in 30–65 % of cases. Immunoglobulin molecules, however, are expressed neither on the surface, nor in cytoplasm of tumor cells.

Aim. To assess cell clonality rate on the basis of rearrangements of immunoglobulin heavy/light chain genes; to determine rearrangement stability at the time of relapse development; to study the range of rearrangements and clonal relationship with primary tumor in metachronous development of mediastinal gray zone lymphoma.

Materials & Methods. The assessment of rearrangements of immunoglobulin heavy/light chain genes was based on molecular analysis of 29 primary tumor biopsies and 4 tissue samples with histologically and immunohistochemically verified relapses or metachronous lymphoma development.

Results. In 16 (55.2 %) out of 29 cases a rearrangement of immunoglobulin heavy chain genes was reported, in 7 (24.1 %) cases a rearrangement of light chain genes was identified, in 6 (20.7 %) cases no rearrangements of immunoglobulin heavy/light chain genes were found. On the basis of immunoglobulin gene analysis in 2 patients with early relapse a tumor clone was detected that was identical with the one identified at the onset of the disease. In 2 patients with complete remission a metachronous development of mediastinal gray zone lymphoma was reported, whereas molecular genetic analysis revealed a change/disappearance of initial clonal rearrangements of immunoglobulin genes.

Conclusion. Total detection rate of B-cell clonality in PMBCL was 79.3 %. Molecular genetic analysis confirmed that initial clonal rearrangements of immunoglobulin genes were preserved in early relapses, and invalidated tumor clonal relationship in a metachronous development of mediastinal gray zone lymphoma.

Keywords: primary mediastinal (thymic) large B-cell lymphoma, rearrangement of immunoglobulin heavy/light chain genes, polymerase chain reaction, metachronous development of lymphoma.

Received: November 2, 2018

Accepted: May 29, 2019

Read in PDF 

REFERENCES

  1. Evans PA, Pott Ch, Groenen PJ, et al. Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia. 2007;21(2):207–14. doi: 10.1038/sj.leu.2404479.

  2. Мангасарова Я.К., Магомедова А.У., Ковригина А.М. и др. Первичная медиастинальная (тимическая) В-крупноклеточная лимфома: диагностика отдаленных экстрамедиастинальных поражений и возможности лечения. Клиническая онкогематология. 2018;11(3):220–6. doi: 21320/2500-2139-2018-11-3-220-226.

    [Mangasarova YaK, Magomedova AU, Kovrigina AM, et al. Primary Mediastinal (Thymic) Large B-Cell Lymphoma: Diagnostics of Extramediastinal Lesions and Treatment Opportunities. Clinical oncohematology. 2018;11(3):220–6. doi: 10.21320/2500-2139-2018-11-3-220-226. (In Russ)]

  3. Harris NL; The International Lymphoma Study Group. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Curr Diagn Pathol. 1995;2(1):58–9. doi: 10.1016/S0968-6053(00)80051-4.

  4. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198(6):851–62. doi: 10.1084/jem.20031074.

  5. Pileri SA, Zinzani PL, Gaidano G, et al. Pathobiology of primary mediastinal B-cell lymphoma. Leuk Lymphoma. 2003;44(Suppl 3):S21–6. doi: 10.1080/10428190310001623810.

  6. Loddenkemper C, Anagnostopoulos I, Hummel M, et al. Differential Emu enhancer activity and expression of BOB.1/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas. J Pathol. 2004;202(1):60–9. doi: 10.1002/path.1485.

  7. De Leval L, Ferry JA, Falini B, et al. Expression of bcl-6 and CD10 in primary Mediastinal large B-cell lymphoma: evidence for derivation from germinal center B cells? Am J Surg Pathol. 2001;25(10):1277–82. doi: 10.1097/00000478-200110000-00008.

  8. Rosenquist R, Lindstrom A, Holmberg D, et al. V(H) gene family utilization in different B-cell lymphoma subgroups. Eur J Haematol. 1999;62(2):123–8. doi: 10.1111/j.1600-0609.1999.tb01732.x.

  9. Zhong DR, Ling Q, Shi XH, et al. Comparative study between primary mediastinal B-cell lymphoma and non-mediastinal diffuse large B-cell lymphoma by immunoglobulin gene rearrangement and Epstein-Barr virus infection detection. J Hematop. 2009;2(1):45–9. doi: 1007/s12308-009-0022-3.

  10. Leithauser F, Bauerle M, Quang Huynh M, et al. Isotype-switched immunoglobulin genes with a high load of somatic hypermutation and lack of ongoing mutational activity are prevalent in mediastinal B-cell lymphoma. 2001;98(9):2762–70; doi: 10.1182/blood.v98.9.2762.

  11. Burack WR, Laughlin TS, Friedberg JW, et al. PCR assays detect B-lymphocyte clonality in formalin-fixed, paraffin-embedded specimens of classical Hodgkin lymphoma without microdissection. Am J Clin Pathol. 2010;134(1):104–11. doi: 10.1309/AJCPK6SBE0XOODHB.

  12. Evens AM, Kanakry JA, Sehn LH, et al. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. Am J Hematol. 2015;90(9):778–83. doi: 10.1002/ajh.24082.

  13. Eberle FC, Salaverria I, Steidl C, et al. Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations. Mod Pathol. 2011;24(12):1586–97. doi: 10.1038/modpathol.2011.116.

  14. Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17(12):2257–317. doi: 10.1038/sj.leu.2403202.

Polymerase Chain Reaction for Prognosis Assessment and Monitoring of the Epstein-Barr Virus-Associated Hodgkin’s Lymphoma

LYMPHOID TUMORS , ,

MA Katin1, IV Zhil’tsov1, VM Semenov1, DK Novik2

1 Vitebsk State Medical University, 27 Frunze pr-t, Vitebsk, Republic of Belarus, 210023

2 Republican Applied Research Center for Radiation Medicine and Human Ecology, 290 Il’icha str., Gomel, Republic of Belarus, 246040

For correspondence: Prof. Ivan Viktorovich Zhil’tsov, MD, PhD, 27 Frunze pr-t, Vitebsk, Republic of Belarus, 210023; Tel.: +375(29)7104368-93-29; e-mail: zhyltsou@tut.by

For citation: Katin NA, Zhil’tsov IV, Semenov VM, Novik DK. Polymerase Chain Reaction for Prognosis Assessment and Monitoring of the Epstein-Barr Virus-Associated Hodgkin’s Lymphoma. Clinical oncohematology. 2018;11(2):182–6.

DOI: 10.21320/2500-2139-2018-11-2-182-186

ABSTRACT

The review provides the analysis of 34 papers on polymerase chain reaction (PCR) as a method of the Epstein-Barr virus (EBV) DNA detection in biological material of patients with EBV-associated cancer diseases including Hodgkin’s lymphoma (HL). A comparative analysis of different methods of EBV DNA detection in biological material is presented. EBV is associated with HL in 20 to 100 % of cases depending on a geographic region and HIV status. EBV-associated HLs are characterized by latency type II. EBV is found in all the atypical cells and can be detected in blood of EBV-associated HL patients by means of the PCR method. The review includes the results of studies on EBV detection using the PCR method compared to in situ methods of hybridization and immunohistochemistry in various EBV-associated cancer diseases including HL. The obtained data indicate that PCR can be used for quantitative determination of EBV DNA in blood plasma of HL patients for therapeutic efficacy monitoring and prognosis assessment of disease and relapses. Quantitative determination of EBV DNA in blood plasma of HL patients using the real time PCR method is a promising technique. Its further practical application requires standardization of the method, larger trials, and comparison to positron emission tomography.

Keywords: Epstein-Barr virus, Hodgkin’s lymphoma, polymerase chain reaction.

Received: December 20, 2017

Accepted: February 28, 2018

Read in PDF 

REFERENCES

  1. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol. 2001;1(1):75–82. doi: 10.1038/35095584.
  2. Murata T. Regulation of Epstein-Barr virus reactivation from latency. Microbiol Immunol. 2014;58(6):307–17. doi: 10.1111/1348-0421.12155.
  3. Shannon-Lowe C, Rickinson AB, Bell AI. Epstein–Barr virus-associated lymphomas. Philos Trans R Soc B Biol Sci. 2017;372(1732):20160271.
  4. Young LS, Murray PG. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene. 2003;22(33):5108–21. doi: 10.1038/sj.onc.1206556.
  5. Rickinson AB, Rowe M, Hart IJ, et al. T-cell-mediated regression of ‘spontaneous’ and of Epstein-Barr virus-induced B-cell transformation in vitro: studies with cyclosporin A. Cell Immunol. 1984;87(2):646–58. doi: 1016/0008-8749(84)90032-7.
  6. Mancao C, Hammerschmidt W. Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. Blood. 2007;110(10):3715–21. doi: 1182/blood-2007-05-090142.
  7. Massini G, Siemer D, Hohaus S. EBV in Hodgkin Lymphoma. Mediterr J Hematol Infect Dis. 2009;1(2):e2009013. doi: 10.4084/MJHID.2009.013.
  8. Flavell KJ, Murray PG. Hodgkin’s disease and the Epstein-Barr virus. Mol Pathol. 2000;53(5):262–9. doi:1136/mp.53.5.262.
  9. Weinreb M, Day PJ, Niggli F, et al. The role of Epstein-Barr virus in Hodgkin’s disease from different geographical areas. Arch Dis Child. 1996;74(1):27–31. doi: 10.1136/adc.74.1.27.
  10. Gandhi MK, Tellam JT, Khanna R. Epstein-Barr virus-associated Hodgkin’s lymphoma. Br J Haematol. 2004;125(3):267–81. doi: 10.1111/j.1365-2141.2004.04902.x.
  11. Glaser SL, Lin RJ, Stewart SL, et al. Epstein-Barr virus-associated Hodgkin’s disease: epidemiologic characteristics in international data. Int J Cancer. 1997;70(4):375–82. doi: 10.1002/(sici)1097-0215(19970207)70:4<375::aid-ijc1>3.0.co;2-t.
  12. Dolcetti R, Boiocchi M, Gloghini A, et al. Pathogenetic and histogenetic features of HIV-associated Hodgkin’s disease. Eur J Cancer. 2001;37(10):1276–87. doi: 10.1016/S0959-8049(01)00105-8.
  13. Gulley ML, Tang W. Laboratory Assays for Epstein-Barr Virus-Related Disease. J Mol Diagn. 2008;10(4):279–92. doi: 2353/jmoldx.2008.080023.
  14. Maurmann S, Fricke L, Wagner H-J, et al. Molecular parameters for precise diagnosis of asymptomatic Epstein-Barr virus reactivation in healthy carriers. J Clin Microbiol. 2003;41(12):5419–28. doi: 10.1128/jcm.41.12.5419-5428.2003.
  15. Hohaus S, Santangelo R, Giachelia M, et al. The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma. Clin Cancer Res. 2011;17(9):2885–92. doi: 10.1158/1078-0432.CCR-10-3327.
  16. Qi Z-L, Han X-Q, Hu J, et al. Comparison of three methods for the detection of Epstein-Barr virus in Hodgkin’s lymphoma in paraffin-embedded tissues. Mol Med Rep. 2013;7(1):89–92. doi: 10.3892/mmr.2012.1163.
  17. Ryan JL, Fan H, Glaser SL, et al. Epstein-Barr virus quantitation by real-time PCR targeting multiple gene segments: a novel approach to screen for the virus in paraffin-embedded tissue and plasma. J Mol Diagn. 2004;6(4):378–85. doi: 1016/S1525-1578(10)60535-1.
  18. Lo YM, Leung SF, Chan LY, et al. Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res. 2000;60(9):2351-5.
  19. To EWH, Chan KCA, Leung S-F, et al. Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. Clin Cancer Res. 2003;9(9):3254–9.
  20. Zhao F, Liu X, Chen X, et al. Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinoma. Oncol Lett. 2015;10(5):2888–94. doi: 3892/ol.2015.3628.
  21. Au W-Y, Pang A, Choy C, et al. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood. 2004;104(1):243–9. doi: 1182/blood-2003-12-4197.
  22. Lei KIK, Chan LYS, Chan W-Y, et al. Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma. Clin Cancer Res. 2002;8(1):29–34.
  23. Hohaus S, Giachelia M, Massini G, et al. Cell-free circulating DNA in Hodgkin’s and non-Hodgkin’s lymphomas. Ann Oncol. 2009;20(8):1408–13. doi: 1093/annonc/mdp006.
  24. Gallagher A, Armstrong AA, MacKenzie J, et al. Detection of Epstein-Barr virus (EBV) genomes in the serum of patients with EBV-associated Hodgkin’s disease. Int J Cancer. 1999;84(4):442–8. doi:1002/(sici)1097-0215(19990820)84:4<442::aid-ijc20>3.0.co;2-j.
  25. Chan KCA, Zhang J, Chan ATC, et al. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res. 2003;63(9):2028–32.
  26. Lei KIK, Chan LYS, Chan WY, et al. Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies. Br J Haematol. 2000;111(1):239–46. doi:1111/j.1365-2141.2000.02344.x.
  27. Gandhi MK, Lambley E, Burrows J, et al. Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin’s lymphoma. Clin Cancer Res. 2006;12(2):460–4. doi: 1158/1078-0432.CCR-05-2008.
  28. Kanakry JA, Li H, Gellert LL, et al. Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood. 2013;121(18):3547–53. doi: 1182/blood-2012-09-454694.
  29. Sinha M, Rao CR, Shafiulla M, et al. Plasma Epstein Barr viral load in adult-onset Hodgkin lymphoma in South India. Hematol Oncol Stem Cell Ther. 2016;9(1):8–13. doi: 10.1016/j.hemonc.2015.11.004.
  30. Spacek M, Hubacek P, Markova J, et al. Plasma EBV-DNA monitoring in Epstein-Barr virus-positive Hodgkin lymphoma patients. APMIS. 2011;119(1):10–6. doi: 1111/j.1600-0463.2010.02685.x.
  31. Welch JJG, Schwartz CL, Higman M, et al. Epstein-Barr virus DNA in serum as an early prognostic marker in children and adolescents with Hodgkin lymphoma. Blood Adv. 2017;1(11):681–4. doi: 1182/bloodadvances.2016002618.
  32. De Paoli P, Pratesi C, Bortolin MT. The Epstein Barr virus DNA levels as a tumor marker in EBV-associated cancers. J Cancer Res Clin Oncol. 2007;133(11):809–15. doi: 1007/s00432-007-0281-2.
  33. Le Q-T, Jones CD, Yau T-K, et al. A Comparison Study of Different PCR Assays in Measuring Circulating Plasma Epstein-Barr Virus DNA Levels in Patients with Nasopharyngeal Carcinoma. Clin Cancer Res. 2005;11(16):5700–7. doi: 1158/1078-0432.CCR-05-0648.
  34. Bortolin MT, Pratesi C, Dolcetti R, et al. Clinical value of Epstein–Barr virus DNA levels in peripheral blood samples of Italian patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Lett. 2006;233(2):247–54. doi: 10.1016/j.canlet.2005.03.015.